Anti-CD3 used in immuno-suppressive drugs for the treatment of leukaemia, offered to oncology researchers via licencing agreement
A UK non-profit organisation is providing access to Anti-CD3 (Anti-Cluster of Differentiation) from its original source Cancer Research UK, to academia and life science industry. The Anti-CD3 antibody is used as a pan T-cell marker in the detection of T-cell populations and in immuno-suppressive drugs for the treatment of leukaemia and is offered to cancer researchers and scientists in academia and industry, via licensing agreement.